312

THREE-YEAR OUTCOMES WITH FIRST-LINE PEMBROLIZUMAB FOR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) WITH A VERY HIGH PD-L1 TUMOR PROPORTION SCORE (TPS) $\geq 90\%$

¹Biagio Ricciuti*, ¹Joao Victor Alessi, ¹Stephanie Alden, ¹Giuseppe Lamberti, ¹Victor Vaz, ¹Adriana Barrichello, ²Lynette Sholl, ¹Mark Awad. ¹Dana-Farber Cancer Institute, Boston, MA, USA; ²Brigham and Women's Hospital, Boston, MA, USA

Background Although 1st-line PD-1 monotherapy has improved survival in patients with advanced NSCLC and a PD-L1 TPS $\geq 50\%$, responses occur in $\sim 45\%$ of patients. We have previously shown that among patients with NSCLC and PD-L1 expression of $\geq 50\%$ treated with 1st-line pembrolizumab, clinical outcomes are significantly improved in those with a PD-L1 TPS of $\geq 90\%$.¹ Here, we report the 3-year follow-up outcomes to 1st-line pembrolizumab in patients with a PD-L1 TPS $\geq 90\%$ vs $< 50-89\%$, and genomic differences between these groups.

Methods Patients with stage IV EGFR/ALK wild type NSCLC and PD-L1 TPS $\geq 50\%$ who received 1st-line pembrolizumab monotherapy at Dana-Farber Cancer Institute were included. Comprehensive tumor genomic profiling was performed to examine genomic correlates of a very high PD-L1 expression on an expanded cohort of NSCLC samples.

Results Among 150 patients included, median age was 69 (range: 46–92), 55.3% were women, 91.9% were current smokers, and 34.0% had a KRAS mutation. At a median follow-up of 38.5 months, median progression-free (mPFS) and overall survival (mOS) in the entire cohort were 4.8 months, and 20.0 months, respectively. When compared to patients with a PD-L1 expression of 50–89% (N=81), those with PD-L1 TPS $\geq 90\%$ (N=69) had a significantly longer mPFS (6.0 vs 3.9 months, HR 0.66, $P=0.02$), and longer mOS (27.0 vs 14.6 months, HR 0.63, $P=0.03$; figure 1). Kaplan-Meier estimates of the 3-year PFS and OS were 23.0% and 43.2% in the PD-L1 TPS $\geq 90\%$ groups, and 8.6% and 24.0% in the PD-L1 TPS 50–89% group, respectively. A PD-L1 TPS $\geq 90\%$ was confirmed to be an independent predictor of improved PFS (HR 0.58, $P=0.02$) and OS (HR 0.57, $P=0.01$) at multivariable analysis. Patients whose tumors had a PD-L1 TPS $\geq 90\%$ were also significantly more likely to complete 35 cycles of therapy compared to those with PD-L1 TPS of 50–89% (17.4% vs 3.7%, $P<0.01$, figure 2). Tumor genomic profiling from 500 NSCLC samples revealed that mutations in STK11, KEAP1, FBXW7, and CTNNB1, which have been previously correlated with immunotherapy resistance, were significantly enriched tumors with a PD-L1 TPS of 50–89% compared to those with a PD-L1 TPS $\geq 90\%$ (figure 3).

Abstract 312 Figure 1 (A) Progression-free and (B) overall survival to 1st line pembrolizumab among patients with PD-L1 TPS $\geq 90\%$ vs 50–89%, at a 3-year follow-up.

Abstract 312 Figure 2 Barplot showing the percentage of patients who completed 35 cycles of pembrolizumab monotherapy in the PD-L1 TPS $\geq 90\%$ and 50–89% groups

Abstract 312 Figure 3 (A) Oncoprint plot showing the top 15 genes mutated in NSCLC with PD-L1 TPS $\geq 90\%$ and 50–89%. (B) Gene mutation enrichment analysis showing differentially mutated genes between NSCLCs with PD-L1 TPS $\geq 90\%$ and 50–89%. ** Adjusted P value < 0.01 ; * Adjusted P value < 0.05 .

Conclusions Pembrolizumab monotherapy continues to demonstrate a meaningful long-term survival benefit at a 3-year follow-up in patients with advanced NSCLC and a PD-L1 TPS $\geq 90\%$ vs 50–89%. NSCLCs with very high PD-L1 TPS have a more favorable genomic profile. These findings have implications for treatment selection and for clinical trial interpretation and design.

REFERENCE

1. Aguilar EJ, Ricciuti B, Gainor JF, *et al.* Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. *Ann Oncol* 2019 October 1; **30**(10):1653–1659

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.312>